| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 83 | 2026 | 3476 | 5.330 |
Why?
|
| Contrast Media | 53 | 2026 | 988 | 4.810 |
Why?
|
| Prostatic Neoplasms | 37 | 2025 | 1775 | 3.460 |
Why?
|
| Image Enhancement | 20 | 2021 | 505 | 1.910 |
Why?
|
| Image Processing, Computer-Assisted | 17 | 2026 | 1261 | 1.490 |
Why?
|
| Algorithms | 13 | 2025 | 1953 | 1.420 |
Why?
|
| Gadolinium DTPA | 16 | 2017 | 233 | 1.370 |
Why?
|
| Models, Theoretical | 9 | 2018 | 494 | 1.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 13 | 2019 | 626 | 1.060 |
Why?
|
| Prostate | 11 | 2023 | 416 | 0.940 |
Why?
|
| Ultrasonic Therapy | 6 | 2012 | 42 | 0.930 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 12 | 2023 | 297 | 0.930 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2021 | 113 | 0.920 |
Why?
|
| Mammary Glands, Animal | 8 | 2020 | 81 | 0.910 |
Why?
|
| Mammary Neoplasms, Experimental | 7 | 2015 | 129 | 0.830 |
Why?
|
| Arteries | 4 | 2021 | 171 | 0.830 |
Why?
|
| Computer Simulation | 11 | 2021 | 1118 | 0.780 |
Why?
|
| Breast Neoplasms | 19 | 2026 | 3110 | 0.780 |
Why?
|
| Ultrasonics | 7 | 2012 | 37 | 0.780 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2020 | 58 | 0.700 |
Why?
|
| Models, Biological | 14 | 2025 | 1768 | 0.690 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 122 | 0.680 |
Why?
|
| Reproducibility of Results | 22 | 2021 | 2715 | 0.670 |
Why?
|
| Muscle, Skeletal | 7 | 2020 | 474 | 0.660 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2014 | 165 | 0.620 |
Why?
|
| Breast | 8 | 2017 | 294 | 0.540 |
Why?
|
| Phantoms, Imaging | 5 | 2015 | 484 | 0.520 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 52 | 0.520 |
Why?
|
| Organometallic Compounds | 4 | 2021 | 139 | 0.520 |
Why?
|
| Animals | 51 | 2025 | 28155 | 0.500 |
Why?
|
| Sensitivity and Specificity | 16 | 2023 | 1922 | 0.490 |
Why?
|
| Rats | 18 | 2017 | 4072 | 0.480 |
Why?
|
| Male | 47 | 2025 | 44557 | 0.470 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 269 | 0.440 |
Why?
|
| Humans | 74 | 2026 | 93515 | 0.400 |
Why?
|
| Hyperthermia, Induced | 5 | 2012 | 75 | 0.390 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2020 | 608 | 0.380 |
Why?
|
| Neoplasms, Experimental | 2 | 2005 | 263 | 0.380 |
Why?
|
| Blood-Brain Barrier | 3 | 2025 | 80 | 0.370 |
Why?
|
| Biomimetic Materials | 1 | 2012 | 25 | 0.360 |
Why?
|
| Neoplasm Transplantation | 6 | 2010 | 399 | 0.350 |
Why?
|
| Mice | 28 | 2025 | 12269 | 0.350 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 23 | 0.350 |
Why?
|
| Tumor Hypoxia | 2 | 2022 | 43 | 0.340 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 48 | 0.340 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 446 | 0.340 |
Why?
|
| Subtraction Technique | 3 | 2009 | 125 | 0.330 |
Why?
|
| Meglumine | 3 | 2021 | 36 | 0.320 |
Why?
|
| Middle Aged | 35 | 2026 | 27573 | 0.320 |
Why?
|
| Female | 44 | 2026 | 48702 | 0.310 |
Why?
|
| Camellia sinensis | 1 | 2009 | 6 | 0.310 |
Why?
|
| Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.310 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 101 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 5 | 2015 | 353 | 0.290 |
Why?
|
| Fluorine | 2 | 2005 | 17 | 0.280 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 164 | 0.280 |
Why?
|
| Fourier Analysis | 5 | 2016 | 123 | 0.280 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 135 | 0.270 |
Why?
|
| Plant Extracts | 1 | 2009 | 247 | 0.260 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 590 | 0.260 |
Why?
|
| Laser Therapy | 2 | 2018 | 151 | 0.250 |
Why?
|
| Carcinogenesis | 2 | 2020 | 235 | 0.250 |
Why?
|
| Adipose Tissue | 2 | 2006 | 270 | 0.250 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2020 | 190 | 0.240 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 12 | 0.240 |
Why?
|
| Aged | 22 | 2026 | 20434 | 0.240 |
Why?
|
| Fluorocarbons | 1 | 2005 | 50 | 0.230 |
Why?
|
| Ultrasonography | 4 | 2014 | 702 | 0.230 |
Why?
|
| Pilot Projects | 10 | 2021 | 917 | 0.220 |
Why?
|
| Echo-Planar Imaging | 5 | 2008 | 51 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2002 | 295 | 0.220 |
Why?
|
| Misonidazole | 2 | 2022 | 18 | 0.220 |
Why?
|
| Prostatectomy | 6 | 2023 | 478 | 0.220 |
Why?
|
| Body Water | 3 | 2004 | 35 | 0.210 |
Why?
|
| Gadolinium | 2 | 2018 | 95 | 0.210 |
Why?
|
| Muscle Neoplasms | 1 | 2004 | 16 | 0.210 |
Why?
|
| Retrospective Studies | 12 | 2026 | 10164 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 147 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 454 | 0.200 |
Why?
|
| Myocardium | 1 | 2006 | 570 | 0.200 |
Why?
|
| Thorax | 2 | 2000 | 78 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 572 | 0.200 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 204 | 0.200 |
Why?
|
| Mice, Transgenic | 7 | 2018 | 1587 | 0.190 |
Why?
|
| Carbon Dioxide | 2 | 2002 | 203 | 0.190 |
Why?
|
| Oxygen | 4 | 2021 | 769 | 0.190 |
Why?
|
| Water | 4 | 2009 | 307 | 0.180 |
Why?
|
| Feasibility Studies | 7 | 2020 | 756 | 0.180 |
Why?
|
| Adult | 21 | 2026 | 27918 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 110 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 280 | 0.170 |
Why?
|
| Neoplasms | 7 | 2020 | 3169 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2023 | 176 | 0.170 |
Why?
|
| Cognition | 1 | 2025 | 627 | 0.160 |
Why?
|
| Rats, Inbred F344 | 4 | 2005 | 160 | 0.160 |
Why?
|
| Leg | 1 | 2021 | 140 | 0.160 |
Why?
|
| Acoustics | 2 | 1997 | 46 | 0.160 |
Why?
|
| Time Factors | 8 | 2025 | 5410 | 0.160 |
Why?
|
| Neoplasm Grading | 4 | 2023 | 402 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 106 | 0.150 |
Why?
|
| Lower Extremity | 1 | 2020 | 99 | 0.150 |
Why?
|
| Electromagnetic Fields | 1 | 1999 | 26 | 0.150 |
Why?
|
| Ischemia | 1 | 2021 | 253 | 0.150 |
Why?
|
| Microvessels | 2 | 2009 | 68 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2585 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 2495 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 34 | 0.140 |
Why?
|
| Dietary Sugars | 1 | 2018 | 8 | 0.140 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.140 |
Why?
|
| Prostatic Hyperplasia | 1 | 2019 | 95 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 813 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 30 | 0.130 |
Why?
|
| Information Storage and Retrieval | 2 | 2010 | 126 | 0.130 |
Why?
|
| Hindlimb | 3 | 2010 | 94 | 0.130 |
Why?
|
| Prospective Studies | 6 | 2018 | 4560 | 0.130 |
Why?
|
| Androgen Antagonists | 3 | 2023 | 143 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2020 | 337 | 0.130 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 9 | 0.130 |
Why?
|
| Wrist | 1 | 2017 | 29 | 0.130 |
Why?
|
| Therapy, Computer-Assisted | 2 | 1995 | 20 | 0.130 |
Why?
|
| Oxides | 3 | 2002 | 42 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2018 | 145 | 0.130 |
Why?
|
| Brain | 3 | 2025 | 2391 | 0.120 |
Why?
|
| Dietary Fats | 1 | 2017 | 135 | 0.120 |
Why?
|
| Iron | 3 | 2002 | 174 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 1799 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 1077 | 0.120 |
Why?
|
| Durapatite | 1 | 2015 | 36 | 0.120 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 1546 | 0.120 |
Why?
|
| Observer Variation | 2 | 2021 | 570 | 0.120 |
Why?
|
| Biopsy | 6 | 2019 | 1175 | 0.120 |
Why?
|
| ROC Curve | 5 | 2018 | 775 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 2006 | 242 | 0.110 |
Why?
|
| Kinetics | 5 | 2023 | 1492 | 0.110 |
Why?
|
| Calcium Oxalate | 1 | 2015 | 188 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 35 | 0.100 |
Why?
|
| Temperature | 4 | 1999 | 424 | 0.100 |
Why?
|
| Gold | 1 | 2014 | 44 | 0.100 |
Why?
|
| Reference Values | 2 | 2015 | 608 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 111 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 284 | 0.100 |
Why?
|
| Crohn Disease | 2 | 2011 | 808 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 36 | 0.100 |
Why?
|
| Thermometers | 3 | 1999 | 6 | 0.100 |
Why?
|
| Models, Anatomic | 2 | 1998 | 87 | 0.100 |
Why?
|
| Manganese Compounds | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 2755 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 69 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 82 | 0.090 |
Why?
|
| Disease Progression | 2 | 2014 | 1531 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 1028 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 282 | 0.090 |
Why?
|
| Transducers | 3 | 1997 | 37 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 4 | 2015 | 117 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 101 | 0.090 |
Why?
|
| Chlorides | 1 | 2012 | 101 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 97 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 192 | 0.090 |
Why?
|
| Scattering, Radiation | 1 | 1992 | 122 | 0.090 |
Why?
|
| Glioma | 1 | 2014 | 301 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 548 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 81 | 0.090 |
Why?
|
| Proteomics | 2 | 2023 | 264 | 0.090 |
Why?
|
| Ascites | 1 | 2011 | 54 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 225 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 302 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 304 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2011 | 91 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2013 | 281 | 0.080 |
Why?
|
| Diffusion | 3 | 2013 | 90 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 754 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 101 | 0.080 |
Why?
|
| Swine | 1 | 2012 | 588 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 452 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2121 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 291 | 0.080 |
Why?
|
| Injections | 3 | 2017 | 124 | 0.080 |
Why?
|
| Pregnancy | 3 | 2025 | 3147 | 0.080 |
Why?
|
| Macrophages | 2 | 2023 | 610 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 349 | 0.080 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2022 | 324 | 0.080 |
Why?
|
| Glucose | 1 | 2012 | 692 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2021 | 229 | 0.070 |
Why?
|
| Extracellular Space | 1 | 2009 | 88 | 0.070 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2009 | 7 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 310 | 0.070 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 48 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 7061 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 441 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 88 | 0.070 |
Why?
|
| Breast Diseases | 2 | 2011 | 99 | 0.070 |
Why?
|
| Artifacts | 2 | 2015 | 243 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 603 | 0.070 |
Why?
|
| Mice, Nude | 4 | 2013 | 824 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2012 | 211 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2006 | 196 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2012 | 277 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2020 | 321 | 0.070 |
Why?
|
| Ferrosoferric Oxide | 3 | 2002 | 18 | 0.060 |
Why?
|
| Magnetite Nanoparticles | 3 | 2002 | 26 | 0.060 |
Why?
|
| Dextrans | 3 | 2002 | 77 | 0.060 |
Why?
|
| Equipment Design | 2 | 2006 | 416 | 0.060 |
Why?
|
| Colitis | 1 | 2010 | 261 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 366 | 0.060 |
Why?
|
| Protons | 2 | 2008 | 102 | 0.060 |
Why?
|
| Materials Testing | 1 | 2006 | 96 | 0.060 |
Why?
|
| Hypoxia | 2 | 2022 | 675 | 0.060 |
Why?
|
| Emulsions | 1 | 2005 | 18 | 0.060 |
Why?
|
| Hot Temperature | 2 | 2014 | 218 | 0.060 |
Why?
|
| Germ-Free Life | 1 | 2025 | 83 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 439 | 0.060 |
Why?
|
| Necrosis | 2 | 1996 | 204 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2011 | 335 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2026 | 391 | 0.050 |
Why?
|
| Spin Labels | 2 | 2015 | 105 | 0.050 |
Why?
|
| Biophysical Phenomena | 2 | 1995 | 124 | 0.050 |
Why?
|
| Biophysics | 2 | 1995 | 153 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1053 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2004 | 292 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 36 | 0.050 |
Why?
|
| Lead | 1 | 2023 | 32 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 727 | 0.050 |
Why?
|
| General Surgery | 2 | 1996 | 248 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 94 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2023 | 111 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 104 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 790 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 120 | 0.050 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2015 | 48 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 646 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 3435 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 103 | 0.050 |
Why?
|
| Models, Statistical | 3 | 2011 | 585 | 0.050 |
Why?
|
| Motion | 1 | 2022 | 94 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 265 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 402 | 0.040 |
Why?
|
| Prognosis | 2 | 2026 | 3911 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 43 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2022 | 187 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 366 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 301 | 0.040 |
Why?
|
| Bacteria | 1 | 2025 | 509 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2021 | 5 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 203 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 9099 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1660 | 0.040 |
Why?
|
| Fibula | 1 | 2021 | 31 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 369 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 104 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 186 | 0.040 |
Why?
|
| Young Adult | 3 | 2017 | 6930 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 362 | 0.040 |
Why?
|
| Indicator Dilution Techniques | 1 | 2019 | 6 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1914 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 1999 | 31 | 0.040 |
Why?
|
| Microwaves | 1 | 1999 | 32 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 179 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 119 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 36 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 78 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 307 | 0.030 |
Why?
|
| Weaning | 1 | 2017 | 26 | 0.030 |
Why?
|
| Radial Artery | 1 | 2017 | 37 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 196 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 1061 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 166 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2479 | 0.030 |
Why?
|
| Time | 1 | 2016 | 79 | 0.030 |
Why?
|
| Sonication | 1 | 1996 | 4 | 0.030 |
Why?
|
| Thermal Conductivity | 1 | 1996 | 4 | 0.030 |
Why?
|
| Mathematics | 1 | 1996 | 180 | 0.030 |
Why?
|
| Auditory Perception | 1 | 1997 | 104 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 2544 | 0.030 |
Why?
|
| Simian virus 40 | 1 | 2015 | 36 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2365 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 1173 | 0.030 |
Why?
|
| Edema | 1 | 2014 | 70 | 0.030 |
Why?
|
| Color | 1 | 2014 | 80 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 123 | 0.030 |
Why?
|
| Mammography | 1 | 2017 | 458 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2850 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 618 | 0.020 |
Why?
|
| Perfusion | 1 | 2014 | 260 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 3502 | 0.020 |
Why?
|
| Streptozocin | 1 | 2012 | 56 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 340 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 107 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 315 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 526 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2441 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 201 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 47 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 371 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1245 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 100 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 212 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 432 | 0.020 |
Why?
|
| Angiography | 1 | 2011 | 192 | 0.020 |
Why?
|
| Ileum | 1 | 2011 | 167 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 404 | 0.020 |
Why?
|
| Extremities | 1 | 2011 | 176 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2017 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 579 | 0.020 |
Why?
|
| Deuterium | 1 | 2008 | 35 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2008 | 103 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 436 | 0.020 |
Why?
|
| Microscopy | 1 | 2008 | 89 | 0.020 |
Why?
|
| Dogs | 2 | 1999 | 634 | 0.020 |
Why?
|
| Endoscopy | 1 | 2011 | 366 | 0.020 |
Why?
|
| Radiology | 1 | 2008 | 192 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1723 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1050 | 0.010 |
Why?
|
| Kidney | 2 | 1999 | 1111 | 0.010 |
Why?
|
| Ribs | 1 | 1999 | 49 | 0.010 |
Why?
|
| Lung | 1 | 1999 | 1366 | 0.010 |
Why?
|